| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/JCEM-72-2-252 |
| P8608 | Fatcat ID | release_hplme3qqwrcuvprokamcxahrpi |
| P953 | full work available at URL | http://academic.oup.com/jcem/article-pdf/72/2/252A/10509327/jcem0252.pdf |
| P698 | PubMed publication ID | 1846868 |
| P2093 | author name string | U. Fischer | |
| J. F. Mortola | |||
| L. Girton | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biochemistry | Q7094 |
| endocrinology | Q162606 | ||
| premenstrual syndrome | Q220193 | ||
| P304 | page(s) | 252A-252F | |
| P577 | publication date | 1991-02-01 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin | |
| Successful Treatment of Severe Premenstrual Syndrome by Combined Use of Gonadotropin-Releasing Hormone Agonist and Estrogen/Progestin* | |||
| P478 | volume | 72 |
| Q34535888 | A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder |
| Q40661005 | A risk-benefit appraisal of drugs used in the management of premenstrual syndrome |
| Q48591929 | Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome |
| Q36519332 | Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? |
| Q43638427 | Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment |
| Q43643998 | Clinical analysis of voice change as a parameter of premenstrual syndrome |
| Q41718913 | Clinical concerns with premenstrual syndrome |
| Q35003765 | Current update of hormonal and psychotropic drug treatment of premenstrual dysphoric disorder |
| Q44107350 | Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. |
| Q51125679 | Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. |
| Q50858412 | Estrogen-serotonin interactions: implications for affective regulation. |
| Q38591320 | GABAA Receptor-Modulating Steroids in Relation to Women's Behavioral Health |
| Q35236480 | Gonadal steroids, brain, and behavior: role of context |
| Q24193315 | Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS) |
| Q40487158 | Histrelin. A review of its pharmacological properties and therapeutic role in central precocious puberty |
| Q41718923 | Hormonal treatment of premenstrual syndrome |
| Q40465606 | Hormones and depression: What are the facts about premenstrual syndrome, menopause, and hormone replacement therapy? |
| Q40839055 | Is premenstrual syndrome an endocrine disorder? |
| Q41476432 | Menstrual migraine. Methods of prevention and control |
| Q34400504 | Neuroactive steroids and central nervous system disorders. |
| Q35683485 | Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics |
| Q40234284 | Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels |
| Q34100435 | Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management. |
| Q34013225 | Premenstrual syndrome. Advances in diagnosis and treatment. |
| Q40499897 | Premenstrual syndrome. Identification and management |
| Q48427598 | Psychoneuroendocrinology of depression. Hypothalamic-pituitary-gonadal axis |
| Q48241829 | Regulation of cyclic AMP level by progesterone in ovariectomized rat neocortex |
| Q44188269 | Relationships between age and symptom severity among women seeking medical treatment for premenstrual symptoms |
| Q35236472 | Reproductive hormonal treatments for mood disorders in women |
| Q28145003 | Sex hormones and the female voice |
| Q40480966 | Steroidal and nonsteroidal "add-back" therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient |
| Q35003756 | The clinical nature and formal diagnosis of premenstrual, postpartum, and perimenopausal affective disorders |
| Q34677268 | The hypothalamic-pituitary-gonadal axis in mood disorders |
| Q34322016 | The premenstrual syndrome--a reappraisal of the concept and the evidence. |
| Q35094630 | The role of hormones and hormonal treatments in premenstrual syndrome. |
| Q36305785 | The use of triptans in the management of menstrual migraine |
| Q35236462 | Treatment of depression associated with the menstrual cycle: premenstrual dysphoria, postpartum depression, and the perimenopause |
| Q28300895 | Treatment of premenstrual dysphoric disorder |
| Q39489200 | Treatment of premenstrual mood symptoms. |
| Q31924845 | Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. |
Search more.